Enanta Pharmaceuticals First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Enanta Pharmaceuticals (NASDAQ:ENTA) First Quarter 2025 Results

Key Financial Results

• Revenue: US$17.0m (down 5.8% from 1Q 2024).
• Net loss: US$22.3m (loss narrowed by 33% from 1Q 2024).
• US$1.05 loss per share (improved from US$1.58 loss in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Enanta Pharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 24%.

Looking ahead, revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 9.2% from a week ago.

Risk Analysis

We should say that we've discovered 3 warning signs for Enanta Pharmaceuticals (1 is a bit unpleasant!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.